Skip to main content
SpringerLink
Log in

Guidelines and Counselling for Treatment Options in the Management of Prostate Cancer

  • Chapter
Prostate Cancer

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 175))

Abstract

Prostate cancer is often a complex disease and one in which many aspects of the disease and the affected patient must be taken into consideration before decisions about diagnostic work-up, treatments, follow-up, etc. can be made. The current chapter reflects the current recommendations of the European Prostate Cancer Guideline Group made on the basis of criteria of evidence-based medicine after extensive review of the literature available up to December 2005.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Krege S, Souchon R, Schmoll HJ; for the German Testicular Cancer Study Group (2001) Interdisciplinary consensus on diagnosis and treatment of testicular germ cell tumours: result of an update conference on evidence-based medicine. Eur Urol 40:372–391

    Article  PubMed  CAS  Google Scholar 

  2. Schmoll HJ, Souchon R, Krege S, et al (2004) European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15:1377–1399

    Article  PubMed  CAS  Google Scholar 

  3. Schrader AJ, Ohlmann CH, Rossmanith S, Hofmann R, Heidenreich A (2006) Impact of evidence-based guidelines on testis cancer management. Cancer 106:313–319

    Article  PubMed  Google Scholar 

  4. Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H, Wolff J, Zattoni F (2005) EAU guidelines on prostate cancer. Eur Urol 48:546–551

    Article  PubMed  CAS  Google Scholar 

  5. US Department of Health and Human services (1992) Public Health Service, Agency for Health Care Policy and Research 1992, pp 115–127. http://www.ahcpr.gov. Cited 29 Sept 2006

    Google Scholar 

  6. Sobin LH, Wittekind C (eds) (2002) TNM classification of malignant tumours, 6th edn. Wiley-Liss, New York

    Google Scholar 

  7. Gleason DF, Mellinger GT (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111:58–64

    PubMed  CAS  Google Scholar 

  8. Oliver SE, May MT, Gunnell D (2001) International trends in prostate-cancer mortality in the ‘PSA-ERA’. Int J Cancer 92:893–898

    Article  PubMed  CAS  Google Scholar 

  9. Helgesen F, Holmberg L, Johansson JE, Bergstrom R, Adami HO (1996) Trends in prostate cancer survival in Sweden, 1960 through 1988, evidence of increasing diagnosis of non-lethal tumours. J Natl Cancer Inst 88:1216–1221

    Article  PubMed  CAS  Google Scholar 

  10. Post PN, Kil PJ, Coebergh JW (1999) Trends in survival of prostate cancer in southeastern Netherlands 1971–1989. Int J Cancer 81:551–554

    Article  PubMed  CAS  Google Scholar 

  11. Bartsch G, Horninger W, Klocker H, et al (2001) Prostate cancer mortality after introduction of prostatespecific antigen mass screening in the Federal State of Tyrol, Austria. Urology 58:417–424

    Article  PubMed  CAS  Google Scholar 

  12. Lu-Yao G, Albertsen PC, Stamford JL, Stukel TA, Walker-Corkery ES, Barry MJ (2002) Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 325:740

    Article  PubMed  Google Scholar 

  13. Schmid HP, Riesen W, Prikler L (2004) Update on screening for prostate cancer with prostate-specific antigen. Crit Rev Oncol Hematol 50:71–78

    PubMed  Google Scholar 

  14. Lodding P, Aus G, Bergdahl S, Frosing R, Lilja H, Pihl CG, Hugosson J (1998) Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng/ml. Prostate specific antigen. J Urol 159:899–903

    Article  PubMed  CAS  Google Scholar 

  15. Horninger W, Reissigl A, Rogatsch H, Volgger H, Studen M, Klocker H, Bartsch G (2000) Prostate cancer screening in the Tyrol, Austria: experience and results. Eur J Cancer 36:1322–1355

    Article  PubMed  CAS  Google Scholar 

  16. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level <or =4.0 ng per milliliter. N Engl J Med 350:2239–2246

    Article  PubMed  CAS  Google Scholar 

  17. Stamey TA (1995) Making the most out of six systemic sextant biopsies. Urology 45:2–12

    Article  PubMed  CAS  Google Scholar 

  18. Aus G, Bergdahl S, Hugosson J, Lodding P, Pihl CG, Pileblad E (2001) Outcome of laterally directed sextant biopsies of the prostate in screened males aged 50–66 years. Implications for sampling order. Eur Urol 139:655–660

    Article  Google Scholar 

  19. Eskew LA, Bare RL, McCullough DL (1997) Systemic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 157:199–202

    Article  PubMed  CAS  Google Scholar 

  20. Morote J, Lopez M, Encabo G, de Torres I (1999) Value of routine transition zone biopsies in patients undergoing ultrasound-guided sextant biopsies for the first time. Eur Urol 35:294–297

    Article  PubMed  CAS  Google Scholar 

  21. Terris MK, Pham TQ, Issa MM, Kabalin JN (1997) Routine transition zone and seminal vesicle biopsies in all patients undergoing transrectal ultrasound guided prostate biopsies are not indicated. J Urol 157:204–206

    Article  PubMed  CAS  Google Scholar 

  22. Applewhite JC, Matlaga BR, McCullough DL (2002) Results of the 5 region prostate biopsy method: the repeat biopsy population. J Urol 168:500–503

    Article  PubMed  Google Scholar 

  23. Roehrborn CG, Pickers GJ, Sanders JS (1996) Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnosis and prostate specific antigen levels. Urology 47:347–352

    Article  PubMed  CAS  Google Scholar 

  24. Djavan B, Ravery V, Zlotta A, Dobronski P, Dobrovits M, Fakhari M, Seitz C, Susani M, Borkowski A, Boccon-Gibod L, Schulman CC, Marberger M (2001) Prospective evaluation of prostate cancer detected on biopsies 1,2,3 and 4; when should we stop? J Urol 166:1679–1683

    Article  PubMed  CAS  Google Scholar 

  25. Zlotta AR, Raviv G, Schulman CC (1996) Clinical prognostic criteria for later diagnosis of prostate carcinoma patients with initial isolated prostatic intraepithelial neoplasia. Eur Urol 30:249–255

    PubMed  CAS  Google Scholar 

  26. Haggman MJ, Macoska JA, Wojno KJ, Oesterling JE (1997) The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues. J Urol 158:12–22

    Article  PubMed  CAS  Google Scholar 

  27. Oyen RH (1996) Imaging modalities in diagnosis and staging of carcinoma of the prostate. In: Brady LW, Heilmann HP, Petrovich Z, Baert L, Brady LW, Skinner DG (eds) Carcinoma of the Prostate. Innovations and Management. Springer-Verlag, Berlin Heidelberg New York, pp 65–96

    Google Scholar 

  28. Rorvik J, Halvorsen OJ, Servoll E, Haukaas S (1994) Transrectal ultrasonography to assess local extent of prostatic cancer before radical prostatectomy. Br J Urol 73:65–69

    PubMed  CAS  Google Scholar 

  29. Smith JA Jr, Scardino PT, Resnick MI, Hernandez AD, Rose SC, Egger MJ (1997) Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective multi-institutional trial. J Urol 157:902–906

    Article  PubMed  Google Scholar 

  30. Liebross RH, Pollack A, Lankford SP, Zagars GK, von Eshenbach AC, Geara FB (1999) Transrectal ultrasound for staging prostate carcinoma prior to radiation therapy: an evaluation based on disease outcome. Cancer 85:1577–1585

    Article  PubMed  CAS  Google Scholar 

  31. Heenan SD (2004) Magnetic resonance imaging in prostate cancer. Prostate Cancer Prostatic Dis 7:282–288

    PubMed  CAS  Google Scholar 

  32. Heidenreich A, Varga Z, Von Knobloch R (2002) Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 167:1681–1686

    Article  PubMed  Google Scholar 

  33. Bader P, Burkhard FC, Markwalder R, Studer UE (2002) Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 168:514–518

    Article  PubMed  Google Scholar 

  34. Golimbu M, Morales P, Al-Askari S, Schulman Y (1981) CAT scanning in staging of prostatic cancer. Urology 18:305–508

    Article  PubMed  CAS  Google Scholar 

  35. Hricak H, Dooms GC, Jeffrey RB, Avallone A, Jacobs D, Benton WK, Narayan P, Tanagho EA (1987) Prostatic carcinoma: staging by clinical assessment, CT and MR imaging. Radiology 162:331–336

    PubMed  CAS  Google Scholar 

  36. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van der Kaa CH, de la Rosette J, Weissleder R (2003) Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348:2491–2499

    Article  PubMed  Google Scholar 

  37. Buell U, Kleinhans E, Zorn-Bopp E, Reuschel W, Muenzing W, Moser EA, Seiderer M (1982) A comparison of bone imaging with Tc-99m DPD and Tc-99m MDP: concise communication. J Nucl Med 23:214–217

    PubMed  CAS  Google Scholar 

  38. Soloway MS, Hardemann SW, Hickey D, Raymond J, Todd B, Soloway S, Moinuddin M (1988) Stratification of patients with metastatic prostate cancer based on the extent of disease on initial bone scan. Cancer 61:195–202

    Article  PubMed  CAS  Google Scholar 

  39. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, Chisholm GD, Moskovitz B, Livne PM, Warner J (1994) Results of conservative management of clinically localized prostate cancer. N Engl J Med 330:242–248

    Article  PubMed  CAS  Google Scholar 

  40. Middleton RG, Thompson IM, Austenfeld MS, Cooner WH, Correa RJ, Gibbons RP, Miller HC, Oesterling JE, Resnick MI, Smalley SR, Wasson JH (1995) Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association. J Urol 154:2144–2148

    Article  PubMed  CAS  Google Scholar 

  41. Thompson IM (1994) Observation alone in the management of localized prostate cancer: the natural history of untreated disease. Urology 43:41–46

    Article  PubMed  CAS  Google Scholar 

  42. Schellhammer PF (1994) Contemporary expectant therapy series: a viewpoint. Urol Symp 44:47–52

    Google Scholar 

  43. Steinberg GD, Bales GT, Brendler CB (1998) An analysis of watchful waiting for clinically localized prostate cancer. J Urol 159:1431–1436

    Article  PubMed  CAS  Google Scholar 

  44. Adolfsson J, Steineck G, Whitmore WF Jr (1993) Recent results of management of palpable clinically localized prostate cancer. Cancer 72:310–322

    Article  PubMed  CAS  Google Scholar 

  45. Albertsen PC, Hanley JA, Gleason DF, Barry MJ (1998) Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280:975–980

    Article  PubMed  CAS  Google Scholar 

  46. Albertsen P, Hanley JA, Murphy-Setzko M (1999) Statistical considerations when assessing outcomes following treatment for prostate cancer. J Urol 162:439–444

    Article  PubMed  CAS  Google Scholar 

  47. Klotz L (2004) Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer. J Urol 172:S48–S50

    Article  PubMed  Google Scholar 

  48. Klotz L (2005) Active surveillance for good risk prostate cancer: rationale, method, and results. Can J Urol 12(Suppl 2):21–24

    PubMed  Google Scholar 

  49. Medical Research Council Prostate Cancer Working Party Investigators Group (1997) Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 79:235–246

    Google Scholar 

  50. Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K (2004) Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: result from the second analysis of the early prostate cancer programme at median follow-up of 5.4 years. J Urol 172:1865–1870

    Article  PubMed  CAS  Google Scholar 

  51. Studer UE, Hauri D, Hanselmann S, Chollet D, Leosinger HJ, Gasser T, Senn E, Trinkler FB, Tscholl RM, Thalmann GN, Dietrich D (2004) Immediate versus delayed hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. J Clin Oncol 22:4109–4118

    Article  PubMed  Google Scholar 

  52. Walsh PC (1997) Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. J Urol 158:1623–1624

    Article  PubMed  CAS  Google Scholar 

  53. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, Andersson SO, Spangberg A, Busch C, Nordling S, Palmgren J, Adami HO, Johansson JE, Norlen BJ, for the Scandinavia Prostatic Cancer Group Study Number 4 (2002) A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347:781–789

    Article  PubMed  Google Scholar 

  54. Huland H (1997) Treatment of localized disease: treatment of clinically localized prostate cancer (T1/T2). In: Murphy G, Denis L, Chatelain C, Griffiths K, Khoury S, Cockett AT (eds) Proceedings of the First International Consultation on Prostate Cancer. Scientific Communication International, Jersey, pp 227–257

    Google Scholar 

  55. Corral DA, Bahnson RR (1994) Survival of men with clinically localized prostate cancer detected in the eighth decade of life. J Urol 151:1326–1329

    PubMed  CAS  Google Scholar 

  56. Lowe BA, Listrom MB (1988) Incidental carcinoma of the prostate: an analysis of the predictors of progression. J Urol 140:1340–1344

    PubMed  CAS  Google Scholar 

  57. Elgamal AA, Van Poppel HP, Van de Voorde WM, Van Dorpe JA, Oyen RH, Baert LV (1997) Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens-a different view. J Urol 157:244–250

    Article  PubMed  CAS  Google Scholar 

  58. Oesterling JE, Suman VJ, Zincke H, Bostwick DG (1993) PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumours. Urol Clin North Am 20:687–693

    PubMed  CAS  Google Scholar 

  59. Epstein JI, Walsh PC, Brendler CB (1994) Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumours found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C). J Urol 152:1721–1729

    PubMed  CAS  Google Scholar 

  60. Schroder FH, Van den Ouden D, Davidson P (1992) The role of surgery in the cure of prostatic carcinoma. Eur Urol Update Series 1:18–23

    Google Scholar 

  61. Gibbons RP (1988) Total prostatectomy for clinically localized prostatic cancer: long-term surgical results and current morbidity. NCI Monogr 7:123–126

    PubMed  Google Scholar 

  62. Pound CR, Partin AW, Epstein JI, Walsh PC (1997) Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 24:395–406

    Article  PubMed  CAS  Google Scholar 

  63. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 360:103–108

    Article  PubMed  CAS  Google Scholar 

  64. Epstein JI, Chan DW, Sokoll LJ, Walsh PC, Cox JL, Rittenhouse H, Wolfert R, Carter HB (1998) Non-palpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 160:2407–2411

    Article  PubMed  CAS  Google Scholar 

  65. Van den Ouden D, Hop W, Schroder FH (1998) Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 160:1392–1397

    Article  PubMed  Google Scholar 

  66. Van Poppel H, Goethuys H, Callewaert P, Vanuytsel L, Van de Voorde WM, Baert L (2000) Radical prostatectomy can provide a cure for well-selected clinical stage T3 prostate cancer. Eur Urol 38:372–379

    Article  PubMed  Google Scholar 

  67. Heidenreich A, Ohlmann CH, Özgür E, Btaun M, Engelmann UH (2005) Extended retropubic radical prostatectomy in clinical stage T3 prostate cancer: significant reduction of positive surgical margins in a case control study. Eur Urol Suppl 4:8

    Google Scholar 

  68. Ghavamian R, Bergstralh EJ, Blute ML, Slezak J, Zincke H (1999) Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol 161:1223–1227

    Article  PubMed  CAS  Google Scholar 

  69. Aus G, Abrahamsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M, Schelin S, Pedersen K (2002) Three-month neoadjuvant hormonal therapy before radical prostatectomy; a 7-year follow-up of a randomized controlled trial. BJU Int 90:561–566

    Article  PubMed  CAS  Google Scholar 

  70. Soloway MS, Pareek K, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Puras-Baez A (2002) Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxM0 prostate cancer: 5-year results. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 167:112–116

    Article  PubMed  Google Scholar 

  71. Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR, Witjes WP (2000) 4-year followup results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-T3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 38:706–713

    Article  PubMed  CAS  Google Scholar 

  72. Van Poppel H, Goethuys H, De Ridder D, Verleyen P, Ackaert K, Werbrouck P, De Coster M, Baert L, the Members of the BUOS (2001) Neoadjuvant therapy before radical prostatectomy: impact on progression free survival. Uro-Oncology 1:301–307

    Google Scholar 

  73. Gleave ME, Goldenbergh L, Chin JL, Warnes J, Saad F, Klotz L, Jewett M, Kassabian V, Chetner M, Dupont C (2003) Randomized comparative study of 3 vs 8 months of neoadjuvant hormonal therapy prior to radical prostatectomy: 3 year PSA recurrence rates. J Urol 169(Suppl):179 Abstr 690

    Google Scholar 

  74. Hanks GE, Hanlon AL, Schultheiss TE, Pinover WH, Movsas B, Epstein BE, Hunt MA (1998) Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 41:501–510

    Article  PubMed  CAS  Google Scholar 

  75. Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, Starkschall G, Rosen I (2000) Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18:3904–3911

    PubMed  CAS  Google Scholar 

  76. Zietman AL, DeSilvio M, Slater JD, et al (2004) A randomized trial comparing conventional dose (70.2 GyE) and high-dose (79.2 GyE) conformal radiation in early stage adenocarcinoma of the prostate: results of an interim analysis of PROG 95-09. Int J Radiat Oncol Biol Phys 60:S131 (Abstr 4)

    Article  Google Scholar 

  77. MRC Radiotherapy Working Party (1998) RT01. A randomized trial of high dose therapy in localized cancer of the prostate using conformal radiotherapy techniques. Clinical protocol. January

    Google Scholar 

  78. Beckendorf V, Guérif S, Le Prise E, Cosset JM, Lefloch O, Chauvet B, Salem N, Chapet O, Bourdin S, Bachaud JM, Maingon P, Lagrange JL, Malissard L, Simon JM, Pommier P, Hay MH, Dubray B, Luporsi E, Bey P (2004) The GETUG 70 Gy vs 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. Int J Radiat Oncol Biol Phys 60:1056–1065

    Article  PubMed  Google Scholar 

  79. Bolla M (1999) Three Dimensional Conformal Radiotherapy alone vs Three Dimensional Conformal Therapy plus adjuvant hormonal therapy in localized T1b-c, T2a, N0, M0 prostatic carcinoma. A Phase III Randomized Study. EORTC protocol 22991. EORTC Data Centre, Brussels

    Google Scholar 

  80. D’Amico A, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW (2004) 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer; a randomized controlled trial. JAMA 292:821–827

    Article  PubMed  CAS  Google Scholar 

  81. Roach M, Marquez C, Yuo H, Narayan P, Coleman L, Nseyo UO, Navvab Z, Carroll PR (1993) Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28:33–37

    Google Scholar 

  82. Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, Amols H, Venkatraman ES, Leibel SA (2002) High dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53:1111–1116

    Article  PubMed  Google Scholar 

  83. Ash D, Flynn A, Batterman J, de Reijke T, Lavagnini P, et al (2000) ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 57:315–321

    Article  PubMed  CAS  Google Scholar 

  84. Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E (2002) Biochemical outcome for hormone naive patients with Gleason score 3+4 versus 4+3 prostate cancer undergoing permanent prostate brachytherapy. Urology 60:98–103

    Article  PubMed  Google Scholar 

  85. Potters L, Cha C, Ashley R, Barbaris H, Leibel S (1998) Is pelvic radiation necessary in patients undergoing prostate brachytherapy? Int J Radiat Oncol Biol Phys 42:300 (Abstr 2146)

    Google Scholar 

  86. Lee LN, Stock RG, Stone NN (2002) Role of neoadjuvant hormonal therapy in the management of intermediate-to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 52:444–452

    Article  PubMed  CAS  Google Scholar 

  87. Galalae RM, Kovacs G, Schultze J, Loch T, Rzehak P, Wilhelm R, Bertermann H, Buschbeck B, Kohr P, Kimmig B (2002) Long term outcome after elective irradiation on the pelvic lymphatics and local dose escalation using high dose rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 52:81–90

    Article  PubMed  Google Scholar 

  88. Bolla M, Van Poppel H, Van Cangh PJ et al (2002) Acute and late toxicity of post operative external irradiation in pT3N0 prostate cancer patients treated within EORTC trial 22911. Int J Rad Oncol Biol Phys; 54(Suppl 2): S62 Abstr 103

    Article  Google Scholar 

  89. Huggins C, Hodges CV (1941) Studies on prostate cancer I. The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293–297

    CAS  Google Scholar 

  90. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D (2001) Phase III radiation therapy oncology group (RTOG) trial 86-10 adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50:1243–1252

    Article  PubMed  CAS  Google Scholar 

  91. Reference deleted in proof

    Google Scholar 

  92. Lawton CA, Winter K, Byhardt R, Sause WT, Hanks GE, Russell AH, Rotman M, Porter A, McGowan DG, DelRowe JD, Pilepich MV (1997) Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Int J Radiat Oncol Biol Phys 38:931–939

    Article  PubMed  CAS  Google Scholar 

  93. Hanks GE, Pajak TF, Porter A, et al (2003) RTOG 92-02: phase III trial of of long term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. J Clin Oncol 21:3972–3978

    Article  PubMed  CAS  Google Scholar 

  94. Huggins C, Stevens RE Jr, Hodges CV (1941) Studies on prostate cancer. II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg 43:209–223

    CAS  Google Scholar 

  95. Jordan WP Jr, Blackard CE, Byar DP (1977) Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. South Med J 70:1411–1413

    PubMed  Google Scholar 

  96. Byar DP (1973) Proceedings: the Veterans Administration Co-operative Urological Research Group studies of cancer of the prostate. Cancer 32:1126–1130

    Article  PubMed  CAS  Google Scholar 

  97. Scherr DS, Pitts WR Jr (2003) The non-steroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer. J Urol 170:1703–1708

    Article  PubMed  CAS  Google Scholar 

  98. Oh WK (2002) The evolving role of estrogen therapy in prostate cancer. Clin Prostate Cancer 1:81–89

    PubMed  CAS  Google Scholar 

  99. Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ (2000) Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 132:566–577

    PubMed  CAS  Google Scholar 

  100. McLeod DG (2003) Hormonal therapy: historical perspective to future directions. Urology 61(Suppl 2A):3–7

    Article  PubMed  Google Scholar 

  101. Oefelein MG, Resnick MI (2003) Effective testosterone suppression for patients with prostate cancer: is there a best castration? Urology 62:207–213

    Article  PubMed  Google Scholar 

  102. Bubley GJ (2001) Is the flare phenomenon clinically significant? Urology 58(Suppl 2A):5–9

    Article  PubMed  CAS  Google Scholar 

  103. FDA/ CDER (2003) FDA approves new drug for advanced prostate cancer. 25 November 2003

    Google Scholar 

  104. Moffat LE (1990) Comparison of Zoladex, diethylstilboestrol and cyproterone acetate treatment in advanced prostate cancer. Eur Urol 18(Suppl 3):26–27

    PubMed  Google Scholar 

  105. Schröder FH, Whelan P, de Reijke TM, Kurth KH, Pavone Macaluso M, Mattelaer J, van Velthoven RF, Debois M, Collette L((2004) Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the ‘uropean Organization for Research and Treatment of Cancer’ (EORTC) Protocol 30892. Eur Urol 45:457–46

    Article  PubMed  CAS  Google Scholar 

  106. Thorpe SC, Azmatullah S, Fellows GJ, Gingell JC, O’Boyle PJ (1996) A prospective, randomized study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma. Eur Urol 29:47–54

    PubMed  CAS  Google Scholar 

  107. McLeod DG (1997) Tolerability of non-steroidal antiandrogens in the treatment of advanced prostate cancer. Oncologist 2:18–27

    PubMed  CAS  Google Scholar 

  108. Narayana AS, Loening SA, Culp DA (1981) Flutamide in the treatment of metastatic carcinoma of the prostate. Br J Urol 53:152–153

    Article  PubMed  CAS  Google Scholar 

  109. Sogani PC, Vagaiwala MR, Whitmore WF Jr (1984) Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. Cancer 54:744–750

    Article  PubMed  CAS  Google Scholar 

  110. Lundgren R (1987) Flutamide as primary treatment for metastatic prostatic cancer. Br J Urol 59:156–158

    PubMed  CAS  Google Scholar 

  111. Delaere KP, Van Thillo EL (1991) Flutamide monotherapy as primary treatment in advanced prostatic carcinoma. Semin Oncol 18(Suppl 6):13–18

    PubMed  CAS  Google Scholar 

  112. Pavone Macaluso M (1994) Flutamide monotherapy versus combined androgen blockade in advanced prostate cancer. Interim report of an Italian multicentre, randomized study. SIU 23rd Congress 354A

    Google Scholar 

  113. Boccon-Gibod L, Fournier G, Bottet P, Marechal JM, Guiter J, Rischman P, Hubert J, Soret JY, Mangin P, Mallo C, Fraysse CE (1997) Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur Urol 32:391–395

    PubMed  CAS  Google Scholar 

  114. Tyrrell CJ, Denis L, Newling DWW, Soloway M, Channer K, Cockshott ID (1998) Casodex 10–200 mg daily, used as monotherapy for the patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group. Eur Urol 33:39–53

    Article  PubMed  CAS  Google Scholar 

  115. Kolvenbag GJ, Nash A (1999) Bicalutamide dosages used in the treatment of prostate cancer. Prostate 39:47–53

    Article  PubMed  CAS  Google Scholar 

  116. Fourcade RO, Chatelain C, Poterre M, et al (1998) An open multicentre randomized study to compare the effect and safety of ‘Casodex’ (bicalutamide) 150 mg monotherapy with castration plus nilutamide in metastatic prostate cancer. Eur Urol 33(Suppl 1):88, 349A

    Google Scholar 

  117. Boccardo F, Barichello M, Battaglia M, Carmignani G, Comeri G, Ferraris V, Lilliu S, Montefiore F, Portoghese F, Cortellini P, Rigatti P, Usai E, Rubagotti A (2002) Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. Eur Urol 42:481–490

    Article  PubMed  CAS  Google Scholar 

  118. Reference deleted in proof

    Google Scholar 

  119. Seidenfeld J, Samson DJ, Aronson N, Albertson PC, Bayoumi AM, Bennett C, Brown A, Garber A, Gere M, Hasselblad V, Wilt T, Ziegler K (1999) Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evidence Report/Technology Assessment No. 4. AHCPR Publication No. 99-E0012. Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services, Rockville

    Google Scholar 

  120. Prostate Cancer Trialists’ Collaborative Group (2000) Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Lancet 355:1491–1498

    Article  Google Scholar 

  121. Schmitt B, Bennett CL, Seidenfeld J, Samson DJ, Wilt TJ (2000) Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev 2:D001526

    Google Scholar 

  122. Schmitt B, Wilt TJ, Schellhammer PF, De Masi V, Sartor O, Crawford ED, Bennett CL (2001) Combined androgen blockade with non-steroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 57:727–732

    Article  PubMed  CAS  Google Scholar 

  123. Samson DJ, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen PC, Bennett CL, Wilt TJ, Aronson N (2002) Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 95:361–376

    Article  PubMed  CAS  Google Scholar 

  124. Fleshner NE, Trachtenberg J (1995) Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side-effects. J Urol 154:1645–1646

    Article  Google Scholar 

  125. Fleshner NE, Fair WR (1996) Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma. Br J Urol 78:907–910

    PubMed  CAS  Google Scholar 

  126. Ornstein DK, Rao GS, Johnson B, Charlton ET, Andriole GL (1996) Combined finasteride and flutamide therapy in men with advanced prostate cancer. Urology 48:901–905

    Article  PubMed  CAS  Google Scholar 

  127. Brufsky A, Fontaine-Rothe P, Berlane K, Rieker P, Jiroutek M, Kaplan I, Kaufman D, Kantoff P (1997) Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology 49:913–920

    Article  PubMed  CAS  Google Scholar 

  128. Kirby R, Robertson C, Turkes A, Griffiths K, Denis LJ, Boyle P, Altwein J, Schröder F((1999) Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group. Prostate 40:105–114

    Article  PubMed  CAS  Google Scholar 

  129. Oh WK, Manola J, Bittman L, Brufsky A, Kaplan ID, Smith MR, Kaufman DS, Kantoff PW (2003) Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. Urology 62:99–104

    Article  PubMed  Google Scholar 

  130. Pether M, Goldenberg SL (2004) Intermittent androgen suppression. BJU Int 93:258–261

    Article  PubMed  CAS  Google Scholar 

  131. Bayoumi AM, Brown AD, Garber AM (2000) Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 92:1731–1739

    Article  PubMed  CAS  Google Scholar 

  132. Reference deleted in proof

    Google Scholar 

  133. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D (1999) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341:1781–1788

    Article  PubMed  CAS  Google Scholar 

  134. Nair B, Wilt T, MacDonald R, Rutks I (2002) Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev 1:CD003506

    PubMed  Google Scholar 

  135. Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Somerfield MR, Ben-Josef E, Middleton R, Porterfield H, Sharp SA, Smith TJ, Taplin ME, Vogelzang NJ, Wade JL Jr, Bennett CL, Scher HI (2004) American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 22:1–15

    Article  Google Scholar 

  136. Ryan CJ, Small EJ (2003) Role of secondary hormonal therapy in the management of recurrent disease. Urology 62(Suppl 6B):87–94

    Article  PubMed  Google Scholar 

  137. Kelly WK, Scher HI (1993) Prostate specific antigen decline after antiandrogen withdrawal syndrome. J Urol 149:607–609

    PubMed  CAS  Google Scholar 

  138. Scher HI, Kelly WK (1993) Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11:1566–1572

    PubMed  CAS  Google Scholar 

  139. Small EJ, Carroll PR (1994) Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 43:408–410

    Article  PubMed  CAS  Google Scholar 

  140. Dawson NA, McLeod DG (1995) Dramatic prostate specific antigen decline in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J Urol 153:1946–1947

    Article  PubMed  CAS  Google Scholar 

  141. Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang N (2004) Antiandrogen withdrawal alone or in combination with ketokonazole in androgenindependent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 22:1025–1033

    Article  PubMed  CAS  Google Scholar 

  142. Ohlmann C, Cordia I, Schilling I, Engelmann U, Heidenreich A (2005) Ketokonazol/hydrocortisone versus estramustine phosphate in the management of PSA progression following primary androgen deprivation for metastatic prostate cancer. Eur Urol Suppl 4:249

    Google Scholar 

  143. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin M, Burch PA, Berry D, Mounpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520

    Article  PubMed  CAS  Google Scholar 

  144. Tannock IF, de Wit R, Berry WR, et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512

    Article  PubMed  CAS  Google Scholar 

  145. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756–1764

    PubMed  CAS  Google Scholar 

  146. Kanthoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ (1999) Hydrocortisine with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 Study. J Clin Oncol 17:2506–2513

    Google Scholar 

  147. Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, Sathyanarayana JR, Yakemchuk VN, Thomas GM, Erlich LE, Crook J, Gulenchyn KY, Hong KE, Wesolowski C, Yardlye J (1993) Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25:805–813

    PubMed  CAS  Google Scholar 

  148. Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IG, Reinhard D, Ezzidin S, Joe A, Roedel R, Fimmers R, Knapp FF Jr, Guhlke S, Biersack HJ (2003) Repeated bone-targeted therapy for hormonerefractory prostate carcinoma: randomized phase II trial with the new high-energy radiopharmaceutical rhenium-188 hydroxyethylidene-diphosphonate. J Clin Oncol 21:2869–2875

    Article  PubMed  CAS  Google Scholar 

  149. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goad JA, Chen B (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458–1468

    PubMed  CAS  Google Scholar 

  150. Heidenreich A, Hofmann R, Engelmann UH (2001) The use of bisphosphonates for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol 165:136–140

    Article  PubMed  CAS  Google Scholar 

  151. Heidenreich A, Elert A, Hofmann R (2002) Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 5:231–235

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Oncological Urology Department of Urology, University of Cologne, Joseph-Stelzmann-Str. 9, 50924, Cologne, Germany

    Axel Heidenreich MD (Prof. Dr. med.)

Authors
  1. Axel Heidenreich MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, 52621, Israel

    Jacob Ramon MD

  2. Lange Gasthuisstraat 35-37, 2000, Antwerp, Belgium

    Louis J. Denis MD, FACS (Director Oncology Centre Antwerp Secretary Europa Uomo) (Director Oncology Centre Antwerp Secretary Europa Uomo)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Heidenreich, A. (2007). Guidelines and Counselling for Treatment Options in the Management of Prostate Cancer. In: Ramon, J., Denis, L.J. (eds) Prostate Cancer. Recent Results in Cancer Research, vol 175. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-40901-4_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-40901-4_9

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-40897-0

  • Online ISBN: 978-3-540-40901-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation